ClinicalTrials.gg
CompletedNCT02666352Updated Sep 17, 2018Results posted

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

A Phase 1 interventional study of Uprifosbuvir and Ruzasvir in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies in Hepatitis C, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Merck & Co., Inc.

Enrollment
63rd of 72
24 · median 113
Started
2016
with 1 other
Phase 1
12 of 110
none open now
Registered
109th of 110
by date

Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 63rd largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 1, and was the 109th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc is open now. The open studies under Hepatitis C, Chronic, anywhere →

Where they have run

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc as a file.
02

Study summary

This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic insufficiency (HI), participants with severe HI, and age-matched healthy control participants.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HI Participants Only:

  • Has a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) HI features of cirrhosis;
  • Part 1 only: Participant's score on the scale ranges from 7 to 9 (moderate HI) at study start.
  • Part 2 only: Participant's score on the Child-Pugh scale ranges from 10 to 15 (severe HI) at study start.

All Participants:

  • (BMI) ≥19 and ≤ 40 kg/m\^2;
  • Continuous non-smokers or moderate smokers (of fewer than 20 cigarettes/day or the equivalent). Participants must agree to consume no more than 10 cigarettes or equivalent/day from the time of screening and throughout the period of sample collection;
  • Health is judged to be stable based on medical history (except for the hepatic impairment condition), physical examination, vital signs, (ECGs), and laboratory safety tests;
  • For female participants of : either sexually inactive for 14 days prior to study start and throughout study or be using an acceptable method;
  • Female participants who are sexually inactive, but become sexually active during the course of the study must agree to use a double physical barrier method (e.g., condom and diaphragm) and a chemical barrier (e.g., spermicide) from the time of the start of sexual activity through completion of the study;
  • Vasectomized or non-vasectomized male participants must agree to use a condom with spermicide or abstain from sexual intercourse from dosing until 90 days after dosing;
  • Male participants must agree not to donate sperm from dosing until 90 days after dosing;
  • Able to swallow multiple tablets and capsules.

Exclusion criteria

Exclusion Criteria:

HI Participants Only:

  • Presence of moderate or severe renal insufficiency (estimated [eGFR] ≤50 mL/min/1.73 m\^2 calculated according to the Modification of Diet in Renal Disease [MDRD] study equation);
  • Presence of drug abuse within the past 6 months prior to dosing.

Healthy Participants Only:

  • Presence of moderate or severe renal insufficiency (eGFR ≤60 mL/min/1.73 m\^2 calculated according to the MDRD study equation);
  • History or presence of alcoholism or drug abuse within the past 2 years prior to dosing;

All Participants:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of study start or expected during the study;
  • History or presence of medical or psychiatric condition or disease;
  • History or presence of or idiosyncratic reaction to the study drugs or related compounds;
  • Female participants who are pregnant or lactating;
  • Positive results at study start for (HIV), surface antigen (HBsAg) or virus (HCV);
  • Unable to refrain from or anticipates the use of any medication or substance (including prescription or over-the-counter, vitamin supplements, natural or herbal supplements) for the prohibited time period;
  • Has taken amiodarone at any time in their life;
  • Donation of blood >500 mL or had significant blood loss within 56 days prior to the dose of study drugs;
  • Plasma donation within 7 days prior to the dose of study drugs;
  • Dosed in another clinical trial within 28 days prior to dosing of study drugs;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Moderate HI Participants

    On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.

    Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    Severe HI Participants

    On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.

    Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    Healthy Participants

    On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.

    Drug: Uprifosbuvir · Drug: Ruzasvir

Interventions

  • A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.

    Also known as: MK-3682

  • A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.

    Also known as: MK-8408

06

What researchers measure

Primary outcomes

  1. Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir

    AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  2. Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir

    AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  3. Area Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir

    AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose

  4. Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir

    Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  5. Plasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir

    C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: 24 hours post-dose

  6. Time to Reach Cmax (Tmax) of Uprifosbuvir

    Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  7. Apparent Terminal Half-Life (t1/2) of Uprifosbuvir

    t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  8. Apparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir

    CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  9. Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir

    Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  10. AUC0-last of Uprifosbuvir Metabolite M5

    AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  11. AUC0-inf of Uprifosbuvir Metabolite M5

    AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  12. AUC0-24hr of Uprifosbuvir Metabolite M5

    AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose

  13. Cmax of Uprifosbuvir Metabolite M5

    Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  14. C24hr of Uprifosbuvir Metabolite M5

    C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: 24 hours post-dose

  15. Lag Time (Tlag) for Uprifosbuvir Metabolite M5

    Tlag is a measure of the time delay between drug administration and the onset of absorption, where onset of absorption is defined as "the time point prior to the first observed/measured non-zero plasma concentration". The Tlag of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm (in this study Tlag was only calculated for the M5 uprifosbuvir metabolite).

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  16. Tmax of Uprifosbuvir Metabolite M5

    Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  17. Apparent t1/2 of Uprifosbuvir Metabolite M5

    Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  18. AUC0-last of Uprifosbuvir Metabolite M6

    AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  19. AUC0-inf of Uprifosbuvir Metabolite M6

    AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  20. AUC0-24hr of Uprifosbuvir Metabolite M6

    AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose

  21. Cmax of Uprifosbuvir Metabolite M6

    Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  22. C24hr of Uprifosbuvir Metabolite M6

    C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: 24 hours post-dose

  23. Tmax of Uprifosbuvir Metabolite M6

    Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  24. Apparent t1/2 of Uprifosbuvir Metabolite M6

    Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  25. AUC0-last of Ruzasvir

    AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  26. AUC0-inf of Ruzasvir

    AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  27. AUC0-24hr of Ruzasvir

    AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose

  28. Maximum Plasma Drug Concentration (Cmax) of Ruzasvir

    Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  29. C24hr of Ruzasvir

    C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: 24 hours post-dose

  30. Tmax of Ruzasvir

    Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  31. Apparent t1/2 of Ruzasvir

    Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  32. CL/F of Ruzasvir

    CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

  33. Vz/F of Ruzasvir

    Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

    Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose

07

Results

Posted Sep 17, 2018

Participant flow

Participants with moderate hepatic insufficiency (HI), severe HI, and healthy controls were recruited at 2 study centers in the United States.

Participant flow — Overall Study
MilestoneModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Started888
Completed888
Not completed000

Outcome measures

PrimaryArea Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir

AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir5.34 (3.55 to 8.05)8.02 (5.32 to 12.1)3.74 (2.48 to 5.63)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.43 · 90% CI 0.89 to 2.31
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 2.15 · 90% CI 1.33 to 3.47
PrimaryArea Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir

AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir5.39 (3.57 to 8.12)8.09 (5.37 to 12.2)3.76 (2.50 to 5.68)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.43 · 90% CI 0.88 to 2.31
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 2.15 · 90% CI 1.33 to 3.48
PrimaryArea Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir

AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
Area Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Area Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir5.35 (3.55 to 8.05)8.02 (5.33 to 12.1)3.74 (2.48 to 5.63)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.43 · 90% CI 0.89 to 2.31
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 2.15 · 90% CI 1.33 to 3.47
PrimaryMaximum Plasma Drug Concentration (Cmax) of Uprifosbuvir

Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · nM
Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir1560 (1030 to 2360)2130 (1410 to 3240)1180 (778 to 1790)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.32 · 90% CI 0.81 to 2.15
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.81 · 90% CI 1.11 to 2.94
PrimaryPlasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir

C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
24 hours post-dose
Reported as:
Median · nM
Plasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Plasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir7.01 (0.00 to 26.9)8.56 (0.00 to 85.5)2.55 (0.00 to 22.3)
PrimaryTime to Reach Cmax (Tmax) of Uprifosbuvir

Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Median · hr
Time to Reach Cmax (Tmax) of Uprifosbuvir
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Time to Reach Cmax (Tmax) of Uprifosbuvir1.00 (0.50 to 4.00)0.50 (0.50 to 1.50)1.25 (0.50 to 3.00)
PrimaryApparent Terminal Half-Life (t1/2) of Uprifosbuvir

t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · hr
Apparent Terminal Half-Life (t1/2) of Uprifosbuvir
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent Terminal Half-Life (t1/2) of Uprifosbuvir3.66 ± 21.73.56 ± 47.53.17 ± 38.5
PrimaryApparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir

CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · L/hr
Apparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir
L/hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir153 ± 39.9102 ± 61.1219 ± 77.6
PrimaryApparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir

Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir
LModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir809 ± 43.8524 ± 57.01000 ± 83.0
PrimaryAUC0-last of Uprifosbuvir Metabolite M5

AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-last of Uprifosbuvir Metabolite M5
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-last of Uprifosbuvir Metabolite M56.46 (4.90 to 8.52)6.79 (5.15 to 8.95)8.11 (6.15 to 10.7)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.80 · 90% CI 0.58 to 1.10
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.84 · 90% CI 0.61 to 1.16
PrimaryAUC0-inf of Uprifosbuvir Metabolite M5

AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-inf of Uprifosbuvir Metabolite M5
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-inf of Uprifosbuvir Metabolite M56.78 (5.15 to 8.93)7.22 (5.48 to 9.50)8.44 (6.41 to 11.1)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.80 · 90% CI 0.58 to 1.11
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.86 · 90% CI 0.62 to 1.18
PrimaryAUC0-24hr of Uprifosbuvir Metabolite M5

AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-24hr of Uprifosbuvir Metabolite M5
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-24hr of Uprifosbuvir Metabolite M52.41 (1.85 to 3.13)2.28 (1.75 to 2.96)3.12 (2.40 to 4.05)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.77 · 90% CI 0.57 to 1.05
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.73 · 90% CI 0.54 to 0.99
PrimaryCmax of Uprifosbuvir Metabolite M5

Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · nM
Cmax of Uprifosbuvir Metabolite M5
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Cmax of Uprifosbuvir Metabolite M5169 (130 to 220)151 (117 to 197)203 (156 to 264)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.83 · 90% CI 0.61 to 1.13
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.75 · 90% CI 0.55 to 1.01
PrimaryC24hr of Uprifosbuvir Metabolite M5

C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
24 hours post-dose
Reported as:
Geometric least squares mean · nM
C24hr of Uprifosbuvir Metabolite M5
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
C24hr of Uprifosbuvir Metabolite M5124 (93.9 to 164)122 (92.8 to 162)150 (114 to 198)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.83 · 90% CI 0.60 to 1.15
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.82 · 90% CI 0.59 to 1.13
PrimaryLag Time (Tlag) for Uprifosbuvir Metabolite M5

Tlag is a measure of the time delay between drug administration and the onset of absorption, where onset of absorption is defined as "the time point prior to the first observed/measured non-zero plasma concentration". The Tlag of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm (in this study Tlag was only calculated for the M5 uprifosbuvir metabolite).

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Median · hr
Lag Time (Tlag) for Uprifosbuvir Metabolite M5
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Lag Time (Tlag) for Uprifosbuvir Metabolite M53.00 (2.00 to 3.00)2.53 (2.00 to 3.00)2.00 (1.50 to 3.02)
PrimaryTmax of Uprifosbuvir Metabolite M5

Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Median · hr
Tmax of Uprifosbuvir Metabolite M5
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Tmax of Uprifosbuvir Metabolite M514.00 (12.00 to 18.00)16.00 (12.00 to 20.00)15.00 (10.00 to 16.00)
PrimaryApparent t1/2 of Uprifosbuvir Metabolite M5

Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · hr
Apparent t1/2 of Uprifosbuvir Metabolite M5
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent t1/2 of Uprifosbuvir Metabolite M524.09 ± 17.225.64 ± 19.223.59 ± 9.7
PrimaryAUC0-last of Uprifosbuvir Metabolite M6

AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-last of Uprifosbuvir Metabolite M6
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-last of Uprifosbuvir Metabolite M628.6 (22.6 to 36.1)27.4 (21.6 to 34.6)41.8 (33.0 to 52.9)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.68 · 90% CI 0.52 to 0.90
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.66 · 90% CI 0.50 to 0.86
PrimaryAUC0-inf of Uprifosbuvir Metabolite M6

AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-inf of Uprifosbuvir Metabolite M6
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-inf of Uprifosbuvir Metabolite M630.1 (23.5 to 38.6)28.7 (22.4 to 36.7)47.0 (36.7 to 60.2)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.64 · 90% CI 0.48 to 0.86
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.61 · 90% CI 0.46 to 0.82
PrimaryAUC0-24hr of Uprifosbuvir Metabolite M6

AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-24hr of Uprifosbuvir Metabolite M6
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-24hr of Uprifosbuvir Metabolite M613.1 (10.6 to 16.1)13.2 (10.8 to 16.3)16.6 (13.5 to 20.4)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.79 · 90% CI 0.62 to 1.01
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.80 · 90% CI 0.63 to 1.02
PrimaryCmax of Uprifosbuvir Metabolite M6

Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · nM
Cmax of Uprifosbuvir Metabolite M6
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Cmax of Uprifosbuvir Metabolite M6851 (675 to 1070)834 (662 to 1050)1070 (846 to 1340)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.80 · 90% CI 0.61 to 1.05
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.78 · 90% CI 0.60 to 1.03
PrimaryC24hr of Uprifosbuvir Metabolite M6

C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
24 hours post-dose
Reported as:
Geometric least squares mean · nM
C24hr of Uprifosbuvir Metabolite M6
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
C24hr of Uprifosbuvir Metabolite M6402 (332 to 487)410 (339 to 497)564 (465 to 683)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.71 · 90% CI 0.57 to 0.89
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.73 · 90% CI 0.58 to 0.91
PrimaryTmax of Uprifosbuvir Metabolite M6

Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Median · hr
Tmax of Uprifosbuvir Metabolite M6
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Tmax of Uprifosbuvir Metabolite M66.00 (2.00 to 12.00)4.00 (3.00 to 8.00)4.00 (3.00 to 6.00)
PrimaryApparent t1/2 of Uprifosbuvir Metabolite M6

Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · hr
Apparent t1/2 of Uprifosbuvir Metabolite M6
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent t1/2 of Uprifosbuvir Metabolite M626.96 ± 19.426.45 ± 31.333.98 ± 37.7
PrimaryAUC0-last of Ruzasvir

AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-last of Ruzasvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-last of Ruzasvir2.30 (1.75 to 3.02)2.70 (2.07 to 3.51)1.98 (1.52 to 2.58)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio (gmr): 1.16 · 90% CI 0.85 to 1.58
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.36 · 90% CI 1.00 to 1.85
PrimaryAUC0-inf of Ruzasvir

AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-inf of Ruzasvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-inf of Ruzasvir2.60 (1.99 to 3.41)3.32 (2.56 to 4.31)2.10 (1.62 to 2.73)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.24 · 90% CI 0.91 to 1.68
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.58 · 90% CI 1.17 to 2.14
PrimaryAUC0-24hr of Ruzasvir

AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Reported as:
Geometric least squares mean · µM*hr
AUC0-24hr of Ruzasvir
µM*hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
AUC0-24hr of Ruzasvir1.04 (0.729 to 1.49)1.05 (0.744 to 1.48)1.17 (0.830 to 1.65)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.89 · 90% CI 0.60 to 1.33
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.90 · 90% CI 0.60 to 1.34
PrimaryMaximum Plasma Drug Concentration (Cmax) of Ruzasvir

Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric least squares mean · nM
Maximum Plasma Drug Concentration (Cmax) of Ruzasvir
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Maximum Plasma Drug Concentration (Cmax) of Ruzasvir105 (65.6 to 167)92.5 (58.9 to 145)137 (87.0 to 215)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.77 · 90% CI 0.45 to 1.30
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 0.68 · 90% CI 0.40 to 1.14
PrimaryC24hr of Ruzasvir

C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
24 hours post-dose
Reported as:
Geometric least squares mean · nM
C24hr of Ruzasvir
nMModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
C24hr of Ruzasvir27.6 (21.4 to 35.7)32.4 (25.2 to 41.5)23.0 (18.0 to 29.5)
Statistical analysis
  • Moderate HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.20 · 90% CI 0.90 to 1.60
  • Severe HI Participants vs Healthy Participants · Geometric least-squares mean ratio: 1.41 · 90% CI 1.06 to 1.87
PrimaryTmax of Ruzasvir

Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Median · hr
Tmax of Ruzasvir
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Tmax of Ruzasvir3.00 (1.50 to 24.00)2.03 (1.50 to 4.00)3.00 (2.00 to 4.00)
PrimaryApparent t1/2 of Ruzasvir

Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · hr
Apparent t1/2 of Ruzasvir
hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Apparent t1/2 of Ruzasvir38.08 ± 23.147.26 ± 36.630.43 ± 14.6
PrimaryCL/F of Ruzasvir

CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · L/hr
CL/F of Ruzasvir
L/hrModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
CL/F of Ruzasvir28.4 ± 36.720.6 ± 52.832.6 ± 54.6
PrimaryVz/F of Ruzasvir

Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.

Time frame:
Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · L
Vz/F of Ruzasvir
LModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Vz/F of Ruzasvir1560 ± 49.81400 ± 37.91430 ± 48.1

Adverse events

Collected over Up to 14 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate HI Participants0/8 (0%)0/8 (0%)1/8 (12.5%)
Severe HI Participants0/8 (0%)0/8 (0%)3/8 (37.5%)
Healthy Participants0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventModerate HI ParticipantsSevere HI ParticipantsHealthy Participants
Abdominal discomfortGastrointestinal disorders0/81/80/8
FlatulenceGastrointestinal disorders1/80/80/8
DizzinessNervous system disorders0/81/80/8
Hepatic encephalopathyNervous system disorders0/81/80/8
HeadacheNervous system disorders0/81/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Moderate HI ParticipantsSevere HI ParticipantsHealthy ParticipantsTotal
Mean58.3 ± 8.755.4 ± 8.257.6 ± 6.357.1 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Moderate HI ParticipantsSevere HI ParticipantsHealthy ParticipantsTotal
Female2338
Male65516
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2017, 11 months.

Results were first posted in Sep 2018, 1 year 8 months after primary completion.

Of 21 phase 1 interventional studies under Hepatitis C, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 11 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2016
First posted
Jan 28, 2016
StartActual
Jan 22, 2016
Primary completionActual
Jan 16, 2017
CompletionActual
Jan 16, 2017
Results first posted
Sep 17, 2018
Last update
Sep 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02666352
Responsible party
Sponsor
First posted
Jan 28, 2016
Start date
Jan 22, 2016
Primary completion
Jan 16, 2017
Completion
Jan 16, 2017
Results posted
Sep 17, 2018
Last update
Sep 17, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Uprifosbuvir · Ruzasvir

Start the discussion